Phio Pharmaceuticals Corp. (NASDAQ: PHIO) announced positive results from its ongoing Phase 1b clinical study for treating cutaneous Squamous Cell Carcinoma, melanoma, and Merkel cell carcinoma.
The company’s INTASYL siRNA gene silencing technology aims to enhance the ability of immune cells to kill cancer cells. In the trial, six patients with cutaneous Squamous Cell Carcinoma and one patient with metastatic melanoma were enrolled.
After completing treatment in the second cohort, two patients showed a complete response (100% tumor clearance), while one patient had a partial response (90% tumor clearance). One patient did not experience any progression. No dose-limiting toxicities or clinically relevant treatment-emergent adverse events were observed.
“We are pleased and encouraged by the profound tumor response in the second dose cohort, coupled with reassuring safety data,” said Mary Spellman MD, Phio’s acting Chief Medical Officer. “We look forward to continued enrollment to assess higher dose concentrations of PH-762.”
These positive results offer promise for Phio’s vision of developing a cancer-free future using INTASYL technology.
Phio Pharmaceuticals Corp. is a clinical-stage biotechnology company advancing its proprietary INTASYL siRNA gene silencing technology to eliminate cancer. The company’s lead clinical program, PH-762, targets PD-1 and has demonstrated enhancement adoptive cell therapy.
Source: https://finance.yahoo.com/news/phio-pharmaceuticals-announces-promising-results-124500940.html